'Small' randomised neo-adjuvant chemotherapy trials in breast cancer reporting on pathological response: more harm than good?

被引：4

作者：

Bonnefoi, H

机构：

[1] Univ Hosp Geneva, Dept Gynecol, Breast & Gynaecol Oncol Med Unit, CH-1211 Geneva, Switzerland

[2] Univ Hosp Geneva, Dept Med, Breast & Gynaecol Oncol Med Unit, CH-1211 Geneva, Switzerland

来源：

ANNALS OF ONCOLOGY | 2005年 / 16卷 / 09期

关键词：

D O I：

10.1093/annonc/mdi288

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1407 / 1410

页数：4

共 22 条

[1] Critical update and emerging trends in epidermal growth factor receptor targeting in cancer [J].

Baselga, J ;

Arteaga, CL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2445-2459

[2] The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27 [J].

Bear, HD ;

Anderson, S ;

Brown, A ;

Smith, R ;

Mamounas, EP ;

Fisher, B ;

Margolese, R ;

Theoret, H ;

Soran, A ;

Wickerham, DL ;

Wolmark, N .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4165-4174

[3]

Bear HD, 2004, BREAST CANCER RES TR, V88, pS16

[4] Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute [J].

Bonadonna, G ;

Valagussa, P ;

Brambilla, C ;

Ferrari, L ;

Moliterni, A ;

Terenziani, M ;

Zambetti, M .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :93-100

[5] Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J].

Buzdar, AU ;

Ibrahim, NK ;

Francis, D ;

Booser, DJ ;

Thomas, ES ;

Theriault, RL ;

Pusztai, L ;

Green, MC ;

Arun, BK ;

Giordano, SH ;

Cristofanilli, M ;

Frye, DK ;

Smith, TL ;

Hunt, KK ;

Singletary, SE ;

Sahin, AA ;

Ewer, MS ;

Buchholz, TA ;

Berry, D ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3676-3685

[6]

Buzdar AU, 2003, BREAST CANCER RES TR, V82, pS69

[7] Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer [J].

Buzdar, AU ;

Singletary, SE ;

Theriault, RL ;

Booser, DJ ;

Valero, V ;

Ibrahim, N ;

Smith, TL ;

Asmar, L ;

Frye, D ;

Manuel, N ;

Kau, SW ;

McNeese, M ;

Strom, E ;

Hunt, K ;

Ames, F ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3412-3417

[8] Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2) [J].

Chua, S ;

Smith, IE ;

A'Hern, RP ;

Coombes, GA ;

Hickish, TF ;

Robinson, AC ;

Laing, RW ;

O'Brien, MER ;

Ebbs, SR ;

Hong, A ;

Wardley, A ;

Mughal, T ;

Verrill, M ;

Dubois, D ;

Bliss, JM .

ANNALS OF ONCOLOGY, 2005, 16 (09) :1435-1441

[9] Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors:: A study of preoperative treatment [J].

Colleoni, M ;

Viale, G ;

Zahrieh, D ;

Pruneri, G ;

Gentilini, O ;

Veronesi, P ;

Gelber, RD ;

Curigliano, G ;

Torrisi, R ;

Luini, A ;

Intra, M ;

Galimberti, V ;

Renne, G ;

Nolè, F ;

Peruzzotti, G ;

Goldhirsch, A .

CLINICAL CANCER RESEARCH, 2004, 10 (19) :6622-6628

[10] Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer [J].

Diéras, V ;

Fumoleau, P ;

Romieu, G ;

Tubiana-Hulin, M ;

Namer, M ;

Mauriac, L ;

Guastalla, JP ;

Pujade-Lauraine, E ;

Kerbrat, P ;

Maillart, P ;

Pénault-Llorca, F ;

Buyse, M ;

Pouillart, P .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (24) :4958-4965

← 1 2 3 →